James E. Flynn just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13D. In the filing, it appears as though James E. Flynn claims to own 3,732,414 shares. This represents 24.08% of Nivalis Therapeutics, Inc..
Please note that typos are common in SEC filings. Please verify the information reported above before acting on it.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Securities to be offered to employees in employee benefit plans - June 21, 2018
Departure of Directors or Certain - June 14, 2018
Nivalis Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - June 11, 2018
Entry into a Material Definitive - June 11, 2018